Loading clinical trials...
Loading clinical trials...
Treatment With Olverembatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Failed to at Least Two Previously Administered Second-generation Tyrosine Kinase Inhibitors: a Prospective, Single-arm Clinical Trial.
The purpose of this trial is to evaluate the efficacy and safety of olverembatinib(HQP1351) in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to at least two second-generation tyrosine kinase inhibitors. The efficacy of olverembatinib is determined by evaluating the major molecular responses(MMR) at the and of 12 months.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Start Date
July 1, 2022
Primary Completion Date
June 30, 2024
Completion Date
June 30, 2025
Last Updated
July 29, 2022
40
ESTIMATED participants
olverembatinib
DRUG
Xin Du, Phd
CONTACT
Lead Sponsor
Shenzhen Second People's Hospital
NCT06119269
NCT04126681
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06516029